OncoMatch/Clinical Trials/NCT07197671
Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer
Is NCT07197671 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies 90Y-NM600 for metastatic cancer.
Treatment: 90Y-NM600 — Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: front-line therapy for metastatic disease — metastatic
Participants must have received and shown evidence of progression or iUPD on at least one front-line therapy for metastatic disease. This can include the immune checkpoint inhibitor they are currently taking.
Lab requirements
Blood counts
ANC ≥ 2000/μL; hemoglobin ≥ 8 g/dL; platelets ≥ 100,000/μL (or ≥ 150,000/μL if on full-dose anticoagulation); lymphocytes ≥ 1000/μL
Kidney function
Cockcroft-Gault calculated creatinine clearance >60 ml/min
Liver function
total bilirubin ≤ 1.5x ULN; AST and ALT ≤ 3.0x ULN
adequate renal function as defined by Cockcroft-Gault calculated creatinine clearance >60 ml/min; adequate hepatic function as defined by: total bilirubin ≤ 1.5x ULN, AST and ALT ≤ 3.0x ULN; adequate hematologic function: ANC ≥ 2000/μL, hemoglobin ≥ 8 g/dL, platelets ≥ 100,000/μL (or ≥ 150,000/μL if on full-dose anticoagulation), lymphocytes ≥ 1000/μL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UW Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify